Extended-release lamotrigine in the treatment of patients with epilepsy

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 9, 2010, Pages 1579-1585

  Syed, Tanvir U ^a   Sajatovic, Martha ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticonvulsant; Antiepileptic drug; Epilepsy; Lamotrigine; Seizures

Indexed keywords

BENZODIAZEPINE; BRIVARACETAM; CARBAMAZEPINE; DIAZEPAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; LORAZEPAM; MIDAZOLAM; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PREGABALIN; RUFINAMIDE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ALBUMIN BLOOD LEVEL; ANTICONVULSANT ACTIVITY; ATAXIA; BIPOLAR DISORDER; BODY WEIGHT; CLINICAL TRIAL; COMPLEX PARTIAL SEIZURE; CREATININE BLOOD LEVEL; DEATH; DISEASE SEVERITY; DIZZINESS; DOCTOR PATIENT RELATION; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG MARKETING; DRUG PACKAGING; DRUG RELEASE; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAPHY; EPILEPSY; EPILEPTIC STATE; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; HEADACHE; HUMAN; HYPONATREMIA; MONOTHERAPY; NAUSEA; NONHUMAN; NYSTAGMUS; PATIENT ATTITUDE; PATIENT COMPLIANCE; PREVALENCE; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SEIZURE; SIDE EFFECT; SLURRED SPEECH; STEVENS JOHNSON SYNDROME; SUSTAINED DRUG RELEASE; THROMBOCYTE COUNT; TONIC CLONIC SEIZURE; TOXIC EPIDERMAL NECROLYSIS; TREATMENT INDICATION; TREATMENT OUTCOME;

ANTICONVULSANTS; DELAYED-ACTION PREPARATIONS; EPILEPSY; HUMANS; TREATMENT OUTCOME; TRIAZINES;

EID: 77952690616     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.485611     Document Type: Review

References (47)

1. Ferguson PL, Chiprich J, Smith G, et al. Prevalence of self-reported epilepsy, health care access, and health behaviors among adults in South Carolina. Epilepsy Behav 2008;13:529-534
2. Kobau R, Zahran H, Grant D, et al. Prevalence of active epilepsy and health-related quality of life among adults with self-reported epilepsy in California: California Health Interview Survey, 2003. Epilepsia 2007;48:1904-1913
3. Kobau R, Gilliam F, Thurman DJ. Prevalence of self-reported epilepsy or seizure disorder and its associations with self-reported depression and anxiety: results from the 2004 Health Styles Survey. Epilepsia 2006;47:1915-1921
4. Centers for Disease Control and Prevention (CDC). Prevalence of self-reported epilepsy -- United States, 1986 -- 1990. MMWR Morb Mortal Wkly Rep 1994;43:810-11, 817-818
5. From the Centers for Disease Control and Prevention. Prevalence of self-reported epilepsy -- United States, 1986 -- 1990. JAMA 1994;272:1893
6. Elliott JO, Moore JL, Lu B. Health status and behavioral risk factors among persons with epilepsy in Ohio based on the 2006 Behavioral Risk Factor Surveillance System. Epilepsy Behav 2008;12:434-444
7. Forsgren L, Hauser WA, Olafsson E, et al. Mortality of epilepsy in developed countries: a review. Epilepsia 2005;46(Suppl 11):18-27
8. Lhatoo SD, Sander JW. Cause-specific mortality in epilepsy. Epilepsia 2005;46(Suppl 11):36-39
9. Nei M, Bagla R. Seizure-related injury and death. Curr Neurol Neurosci Rep 2007;7:335-341
10. Shackleton DP, Westendorp RG, Kasteleijn-Nolst Trenite DG, et al. Survival of patients with epilepsy: an estimate of the mortality risk. Epilepsia 2002;43:445-450
11. Klenerman P, Sander JW, Shorvon SD. Mortality in patients with epilepsy: a study of patients in long term residential care. J Neurol Neurosurg Psychiatry 1993;56:149-152
12. Neufeld MY, Vishne T, Chistik V, Korczyn AD. Life-long history of injuries related to seizures. Epilepsy Res 1999;34:123-127
13. Faught E, Duh MS, Weiner JR, et al. Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM Study. Neurology 2008;71:1572-1578
14. DiIorio C, Osborne Shafer P, Letz R, et al. The association of stigma with self-management and perceptions of health care among adults with epilepsy. Epilepsy Behav 2003;4:259-267
15. Cramer JA, Glassman M, Rienzi V. The relationship between poor medication compliance and seizures. Epilepsy Behav 2002;3:338-342
16. Davis KL, Candrilli SD, Edin HM. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population. Epilepsia 2008;49:446-454
17. Elwes RD, Johnson AL, Shorvon SD, Reynolds EH. The prognosis for seizure control in newly diagnosed epilepsy. N Engl J Med 1984;311:944-947
18. First Seizure Trial Group (FIR.S.T. Group). Randomized clinical trial on the efficacy of antiepileptic drugs in reducing the risk of relapse after a first unprovoked tonic-clonic seizure. Neurology 1993;43:478-483
19. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-319
20. Noyer M, Gillard M, Matagne A, et al. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol 1995;286:137-146
21. Francis J, Burnham WM. 3[H]Phenytoin identifies a novel anticonvulsant-binding domain on voltage-dependent sodium channels. Mol Pharmacol 1992;42:1097-1103
22. McLean MJ, Macdonald RL. Carbamazepine and 10,11-epoxycarbamazepine produce use- and voltage-dependent limitation of rapidly firing action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther 1986;238:727-738
23. Lang DG, Wang CM, Cooper BR. Lamotrigine, phenytoin and carbamazepine interactions on the sodium current present in N4TG1 mouse neuroblastoma cells. J Pharmacol Exp Ther 1993;266:829-835
24. McLean MJ, Bukhari AA, Wamil AW. Effects of topiramate on sodium-dependent action-potential firing by mouse spinal cord neurons in cell culture. Epilepsia 2000;41(Suppl 1):S21-4
25. Lloyd P, Flesch G, Dieterle W. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 1994;35(Suppl 3):S10-13
26. Stephens WP, Coe JY, Baylis PH. Plasma arginine vasopressin concentrations and antidiuretic action of carbamazepine. Br Med J 1978;1:1445-1447
27. Macdonald RL, McLean MJ. Anticonvulsant drugs: mechanisms of action. Adv Neurol 1986;44:713-736
28. MacDonald RL, Twyman RE. Kinetic properties and regulation of GABAA receptor channels. Ion Channels 1992;3:315-343
29. Study RE, Barker JL. Diazepam and (--)-pentobarbital: fluctuation analysis reveals different mechanisms for potentiation of gamma-aminobutyric acid responses in cultured central neurons. Proc Natl Acad Sci USA 1981;78:7180-7184
30. Sofou K, Kristjansdottir R, Papachatzakis NE, et al. Management of prolonged seizures and status epilepticus in childhood: a systematic review. J Child Neurol 2009;24:918-926
31. Sills GJ, Brodie MJ. Update on the mechanisms of action of antiepileptic drugs. Epileptic Disord 2001;3:165-172
32. Luszczki JJ. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacol Rep 2009;61:197-216
33. Rheims S, Ryvlin P. Once-daily lamotrigine extended release for epilepsy management. Expert Rev Neurother 2009;9:167-173
34. Lamictal XR package insert (US). GlaxoSmithKline. 18 January 2010
35. Hainsworth AH, Spadoni F, Lavaroni F, et al. Effects of extracellular pH on the interaction of sipatrigine and lamotrigine with high-voltage-activated (HVA) calcium channels in dissociated neurones of rat cortex. Neuropharmacology 2001;40:784-791
36. Poolos NP, Migliore M, Johnston D. Pharmacological upregulation of h-channels reduces the excitability of pyramidal neuron dendrites. Nat Neurosci 2002;5:767-774
37. Huang CW, Huang CC, Liu YC, Wu SN. Inhibitory effect of lamotrigine on A-type potassium current in hippocampal neuron-derived H19-7 cells. Epilepsia 2004;45:729-736
38. Valles AS, Garbus I, Barrantes FJ. Lamotrigine is an open-channel blocker of the nicotinic acetylcholine receptor. Neuroreport 2007;18:45-50
39. Rambeck B, Wolf P. Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 1993;25:433-443
40. Werz MA. Pharmacotherapeutics of epilepsy: use of lamotrigine and expectations for lamotrigine extended release. Ther Clin Risk Manag 2008;4:1035-1046
41. Sabers A, Ohman I, Christensen J, Tomson T. Oral contraceptives reduce lamotrigine plasma levels. Neurology 2003;61:570-571
42. Christensen J, Petrenaite V, Atterman J, et al. Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. Epilepsia 2007;48:484-489
43. Tompson DJ, Ali I, Oliver-Willwong R, et al. Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study). Epilepsia 2008;49:410-417
44. Fuller MA, Sajatovic M, editors. Drug information handbook for psychiatry: a comprehensive reference of psychotropic, non-psychotropic, and herbal agents. 6th edition. Lexi-Comp, Hudson, OH; 2006
45. Naritoku DK, Warnock CR, Messenheimer JA, et al. Lamotrigine extended-release as adjunctive therapy for partial seizures. Neurology 2007;69:1610-1618
46. Faught RE, Weiner JR, Guerin A, et al. Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study. Epilepsia 2009;50:501-509
47. Eatock J, Baker GA. Managing patient adherence and quality of life in epilepsy. Neuropsychiatr Dis Treat 2007;3:117-131